Form Type:  425
Filing Date:  1/13/2021 
CIK:  0001731831 
Address:  101 MONTGOMERY STREET, SUITE 2550 
City, State, Zip:  SAN FRANCISCO, California 94104 
Telephone:  650-391-9740 
Fiscal Year:  12/31 
Description of Business
We are a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. We seek to treat this well-defined family of diseases by targeting them at their collective source by stabilizing TTR. TTR is a protein that occurs naturally in the form of a tetramer (a molecular structure consisting of four identical subunits, or monomers) and performs multiple beneficial roles, including the transport of essential hormones and vitamins. Over 25 years of research have shown that ATTR is uniformly driven by destabilization of the TTR tetramer, stemming from either specific gene mutations or aging. TTR destabilization drives an irreversible dissociation of the tetramer into monomers, which subsequently aggregate and deposit predominantly in the heart and peripheral nervous system, leading to organ damage, loss of organ function, and eventual death if left untreated.
Register and access this filing in:     
  FORM 425